JAMP FENOFIBRATE E
As listed in the register: JAMP FENOFIBRATE E
48 mg · tablet
- Prescription only
- Heart, blood pressure and circulation
- Active substance
- Fenofibrate
- Made by
- Jamp Pharma Corporation
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Fenofibrate). It describes the substance, not this exact product.
The active moiety of fenofibrate tablets is fenofibric acid.
The pharmacological effects of fenofibric acid in both animals and humans have been studied through oral administration of fenofibrate.
Racial and Ethnic Groups The influence of race on the pharmacokinetics of fenofibrate has not been studied, however fenofibrate is not metabolized by enzymes known for exhibiting inter-ethnic variability.
Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine.
Effect of Food Exposure to fenofibric acid in plasma, as measured by C max and AUC, is not significantly different when a single 145 mg dose of fenofibrate is administered under fasting or nonfasting conditions.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-09-09
Safety of the active substance
From the US prescribing label for the same active substance (Fenofibrate). It describes the substance, not this exact product.
- Fenofibrate is contraindicated in patients with: Severe renal impairment, including those with end-stage renal disease (ESRD) and those receiving dialysis [see Clinical Pharmacology (12.3) ].
- Active liver disease, including those with unexplained persistent liver function abnormalities [see Warnings and Precautions (5.2) ].
- Pre-existing gallbladder disease [see Warnings and Precautions (5.5) ].
- Hypersensitivity to fenofibrate, fenofibric acid, or any of the excipients in fenofibrate tablets.
The most frequent events, causing discontinuation of fenofibrate treatment in 1.6% of patients in double-blind trials.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States27 matching products
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Jamp Pharma Corporation |
|---|---|
| Active substance | Fenofibrate |
| Used in | Heart, blood pressure and circulation |
| Strength | 48 mg |
| Form | tablet |
| Classification | C10AB05 · Heart, blood pressure and circulation |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Approved |
| Marketed | No — authorised but not currently marketed, according to the register |
| DIN | 02564238 |
| DPD drug code | 106694 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- tablet2 products
- 48 mg
- 145 mg
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.